FDA approves 1st immunotherapy breast cancer drug

March 13, 2019 11:10 AM | Anonymous

March 13, 2019, CNN via WebMD 

The U.S. Food and Drug Administration has given its blessing to the first immunotherapy regimen for breast cancer. The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) was given accelerated approval for triple-negative breast cancer that is locally advanced or has spread, cannot be surgically removed, and has cells that have a protein called PD-L1, CNN reported.

Read more.

Powered by Wild Apricot Membership Software